Global Minimal Residual Disease (MRD) Testing Market to Reach US$ 5.1 Billion by 2032, Propelled by Increasing Prevalence of Cancer

October 10, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Minimal Residual Disease (MRD) Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), and Others), Application (Hematological Malignancy, Solid Tumors), End User (Hospitals and Speciality Clinics, Diagnostic Laboratories, Academic and Research Institutes, and Others), and Region 2024-2032,“ the global minimal residual disease (MRD) testing market size reached US$ 2.1 Billion in 2023. Minimal residual disease (MRD) testing is a sophisticated diagnostic approach employed in the field of oncology. This testing method is designed to detect the presence of cancer cells that remain in the patient after treatment, at levels undetectable through standard diagnostic techniques. Utilizing highly sensitive molecular and immunological methods, such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS), MRD testing can identify the residual disease at a cellular level. These advanced techniques provide an unparalleled precision that helps clinicians assess treatment efficacy, stratify patient risk, and decide upon subsequent treatment strategies. Some of the advantages of MRD testing include the early identification of treatment failure, allowing for timely intervention and potentially better patient outcomes.

Global Minimal Residual Disease (MRD) Testing Market Trends:

The global market is majorly driven by the increasing prevalence of cancer that is demanding advanced diagnostic methods. In line with this, the growing reliance on targeted therapies and personalized medicine is creating a fertile ground for MRD Testing. Also, substantial investments in oncological research are laying the groundwork for further refinement of this diagnostic method, thereby fueling the growth of the market. Moreover, continual technological advancements in molecular diagnostics are amplifying the test's accuracy and applicability, which in turn is stimulating the market. In addition to this, the growing pool of FDA-approved tests fortifying the clinical credibility of MRD testing is resulting in a higher adoption. Furthermore, healthcare providers are acknowledging its role in patient risk stratification, which is creating a positive market outlook. The market is further strengthened by the expansion of healthcare infrastructure in emerging economies. Some of the other factors contributing to the market include the growing public awareness about early cancer detection, the initiation of educational programs by governments and non-profits concerning cancer diagnostics, and the emergence of telehealth as a complementary pathway for discussing diagnostic results. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 5.1 Billion by 2032, exhibiting a CAGR of 10.21% during 2024-2032.

Market Summary:

  • Based on the technology, the market has been segmented into flow cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. Among these, polymerase chain reaction (PCR) represents the largest market segment. 
  • On the basis of the application, the market has been divided into hematological malignancy (leukemia and lymphoma) and solid tumors. Among these, hematological malignancy (leukemia and lymphoma) accounts for the dominant market share. 
  • Based on the end user, the market has been categorized into hospitals and speciality clinics, diagnostic laboratories, academic and research institutes, and others. Between these, hospitals and speciality clinics accounts for the biggest segment in the market. 
  • On the geographical front, the market has been segregated into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa. At present, North America holds the leading position in the market. 
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., and Sysmex Corporation.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Technologies Covered Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others
Applications Covered
  • Hematological Malignancy: Leukemia, Lymphoma
  • Solid Tumors
End Users Covered Hospitals and Speciality Clinics, Diagnostic Laboratories, Academic and Research Institutes, Others
Regions Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Minimal Residual Disease (MRD) Testing Market to Reach US$ 5.1 Billion by 2032, Propelled by Increasing Prevalence of Cancer
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More